Chiesi expands La Chaussée-Saint-Victor site to manufacture next-gen inhalers
Charlie Blackie-Kelly | November 10, 2025 | News story | Manufacturing and Production | Chiesi, Metered Dose Inhalers, Site Expansion, respiratory diseases
Chiesi, a biopharma group focused on treating respiratory diseases, has inaugurated an expansion of its manufacturing and industrial site in La Chaussée-Saint-Victor, near Blois, in France.
The facility will serve as the group’s manufacturing hub for its next-generation metered dose inhalers (MDIs), supporting Chiesi’s corporate social responsibility (CSR) and environmental sustainability goals.
Since 2019, the company has invested more than €400m in the research and development of its Carbon Minimal Inhaler (CMI) platform. These pressurised MDIs use next-generation propellants designed to cut the carbon footprint of each device by up to 90%. Chiesi reports that the CMI platform maintains comparable safety, efficacy and usability for patients while significantly reducing emissions.
Attending a ceremony at the site, Maria Paola Chiesi, Chiesi Group Vice Chair, commented: “This inauguration represents much more than an industrial success. It illustrates our commitment to creating an environment where everyone contributes to a common goal: innovating for the well-being of the patients and the communities we serve, while safeguarding our planet.”
The company said the expansion will initially create around 50 new direct and indirect roles, with total employment expected to reach 300 by 2026.
Chiesi has invested more than €100m to strengthen the sustainability and resilience of its supply chain. This includes the development of a French Centre of Excellence, increased manufacturing capacity to meet rising global demand, and initiatives to make its sites and operations more environmentally sustainable.
Related Content
NICE recommends treatment for rare genetic eye disorder
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending …
Osivax publishes positive results from trial of influenza vaccine candidate
French biopharma, Osivax, has announced positive results from its phase 2 study, OVX836-004, into OVX836, …
Great Place To Work® and Fortune Name Chiesi Group No. 23in 2024 World’s Best Workplaces™ List
Chiesi is the only European pharmaceutical company and the first Italian company ever to be …
